LJAC
NAMS icon

L.J. Altfest & Co’s NewAmsterdam Pharma NAMS Stock Holding History

L.J. Altfest & Co’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,934
Closed -$446K – 338
2026
Q1 		$446K Buy
+13,934
New +$454K 0.05% 233

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

L.J. Altfest & Co's NAMS Position: Q2 2026 in Review

L.J. Altfest & Co sold out of NewAmsterdam Pharma (NAMS) in Q2 2026, closing a stake of 13,934 shares — an estimated $446K sold.

L.J. Altfest & Co first reported a position in NAMS in Q1 2026 and held it in 1 quarter. The position peaked at $446K in Q1 2026. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • L.J. Altfest & Co reported no remaining NewAmsterdam Pharma position as of Q2 2026 after selling out during the quarter.
  • L.J. Altfest & Co sold 13,934 NewAmsterdam Pharma shares in Q2 2026, an estimated $446K.
  • L.J. Altfest & Co first reported a position in NewAmsterdam Pharma in Q1 2026 and held it in 1 quarter.
  • L.J. Altfest & Co's NewAmsterdam Pharma position peaked at $446K in Q1 2026.
  • 194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on L.J. Altfest & Co's 13F filing for Q2 2026, filed 30 Jul 2026.